Angela Stewart | Washington State University (original) (raw)

Address: Yakima, Washington, United States

less

Related Authors

Lukas Kubala

Institute of Biophysics, Chinese Academy of Sciences

Michael Darracq

Uploads

Papers by Angela Stewart

Research paper thumbnail of Hemodynamic and Cardiovascular Effects of Nitric Oxide Modulation in the Therapy of Septic Shock

Pharmacotherapy, 2000

Nitric oxide synthase (NOS) of the inducible subtype (iNOS) plays a pivotal role in vasodilation ... more Nitric oxide synthase (NOS) of the inducible subtype (iNOS) plays a pivotal role in vasodilation associated with sepsis. Various biochemical pathways are involved, revealing targets for inhibiting the consequence of iNOS activation. Interactions of transcription factors, inducers, cofactors, and regulators of iNOS are important in understanding the development of iNOS inhibitors. Inhibition through L-arginine analogs, depletion of arginine, inhibition of cofactors, modulating gene transcription, and scavenging nitric oxide have been studied. Human studies were conducted only with nonselective L-arginine analogs. Reduction of mortality from sepsis was not reported. It is anticipated that iNOS-specific compounds will be clinically useful. The focus of future human trials will be on these agents. Although ideal therapy for treating vasodilation from sepsis is not available, research into the pathophysiology of NOS in sepsis clarified the complexities surrounding this therapeutic dilemma. NOS = nitric oxide synthase; nNOS = neuronal NOS; iNOS = inducible NOS; eNOS = endothelial NOS; NMDA = N-methyl-D-aspartate; ADP = adenosine diphosphate.

Research paper thumbnail of Hemodynamic and Cardiovascular Effects of Nitric Oxide Modulation in the Therapy of Septic Shock

Pharmacotherapy, 2000

Nitric oxide synthase (NOS) of the inducible subtype (iNOS) plays a pivotal role in vasodilation ... more Nitric oxide synthase (NOS) of the inducible subtype (iNOS) plays a pivotal role in vasodilation associated with sepsis. Various biochemical pathways are involved, revealing targets for inhibiting the consequence of iNOS activation. Interactions of transcription factors, inducers, cofactors, and regulators of iNOS are important in understanding the development of iNOS inhibitors. Inhibition through L-arginine analogs, depletion of arginine, inhibition of cofactors, modulating gene transcription, and scavenging nitric oxide have been studied. Human studies were conducted only with nonselective L-arginine analogs. Reduction of mortality from sepsis was not reported. It is anticipated that iNOS-specific compounds will be clinically useful. The focus of future human trials will be on these agents. Although ideal therapy for treating vasodilation from sepsis is not available, research into the pathophysiology of NOS in sepsis clarified the complexities surrounding this therapeutic dilemma. NOS = nitric oxide synthase; nNOS = neuronal NOS; iNOS = inducible NOS; eNOS = endothelial NOS; NMDA = N-methyl-D-aspartate; ADP = adenosine diphosphate.

Log In